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ABSTRACT: We demonstrate the application of a multilaminar flow platform, in which functionalised magnetic particles are de-
flected through alternating laminar flow streams of reagents and washing solutions via an external magnet, for the rapid detection of 
the inflammatory biomarker, C-reactive protein (CRP). The two-step sandwich immunoassay was accomplished in less than 60 
seconds, a vast improvement on the 80-300 min timeframe required for ELISA and the 50 min necessary for off-chip magnetic 
particle-based assays. The combination of continuous flow and a stationary magnet enables a degree of autonomy in the system, 
while a detection limit of 0.87 µg mL-1 makes it suitable for the determination of CRP concentrations in clinical diagnostics. Its 
applicability was further proven by assaying real human serum samples and comparing those results to values obtained using stand-
ard ELISA tests. 
INTRODUCTION 
C-reactive protein (CRP), an acute phase protein, is an in-
flammatory biomarker found in blood whose concentration 
increases when the body experiences inflammation or infec-
tion, and as such is important in clinical diagnostics.1,2 Normal 
levels are typically 1-10 µg mL-1 while levels higher than this 
can indicate inflammation, viral infection (10-40 µg mL-1) or 
bacterial infection (40-200 µg mL-1). There is also evidence 
that CRP may be an indicator of cardiovascular disease 
(CVD),3-6 with concentrations below 1 µg mL-1 suggesting a 
low risk of developing CVD, while levels of 1-3 µg mL-1 indi-
cate an average risk and those above 3 µg mL-1 suggest a high 
risk.7 For these tests, high sensitivity CRP (hs-CRP) tech-
niques are usually performed, employing enzyme-linked 
immunosorbent assays (ELISA) or nephelometry. While 
ELISA has very low detection limits for CRP (1 ng mL-1),8 the 
limits for nephelometry are relatively high ( commonly >5 µg 
mL-1),9 and both methods can be time-consuming, with ELISA 
tests in particular requiring ~80 min.  
The use of magnetic particles as solid supports has recently 
become increasingly popular for clinical diagnostics due to 
their small sizes (0.2-100 µm), high surface-to-volume ratios, 
variety of biomolecules surface functionalities (e.g. antibodies, 
DNA), and the ease with which they can be manipulated via 
an applied magnetic field.10,11 With these beneficial properties, 
they have found use in a number of immunoassay 
procedures,11 including the detection of CRP.12-15 However, 
conventional magnetic particle-based assays that take place in 
a well or vial require many manual reaction and washing steps 
(Figure 1a,b) that make this batch process laborious and time-
consuming (~50 min). 
In recent years, microfluidic devices16 have been developed 
for performing immunoassays17,18 within networks of channels 
that have dimensions on the order of 10-100 µm. Such devices 
allow very small volumes to be processed, reducing sample 
and reagent volumes as well as waste production, while diffu-
sion distances are shortened to allow fast and controlled reac-
tions. Several microfluidic systems have been developed for 
CRP immunoassays,8,9,19-28 and while some feature impressive 
limits of detection (0.01-100 ng mL-1),9,21-23,25,27 they typically 
require >20 min with only a handful of exceptions.23,25 Often 
these devices require complex fabrication procedures to pro-
duce integrated components, arrays, or stencils. The majority 
also require fluorescence imaging of a large area, which may 
contain arrays of detection zones, in order to perform an anal-
ysis, thus requiring fluorescence microscopy which limits the 
path to overall miniaturisation and portability. 
The combination of magnetic particles in microfluidic plat-
forms has exploited the benefits of both fields for a number of 
processes,29-31 including immunoassays.32 However, many 
techniques involve the trapping of particles and subsequent 
exposure to reagents,9,37-40 hence suffering from the same labo-
rious and time-consuming steps as conventional magnetic 
particle assays. A recent solution to this problem has been the 
introduction of “multilaminar flow” procedures for performing 
assays and other processes.33 Here, alternating streams of rea-
gents and washing buffer solutions are generated across a 
chamber. Functionalised particles are then deflected laterally 
through the each of the streams, allowing consecutive reaction 
and washing steps to take place. This technique effectively 
reduces multi-stage processes into a single, automated step 
that reduces assay times considerably and eliminates the mul-
tiple manual operations associated with batch assays. Magnet-
ic particles provide an excellent solid phase for this process as 
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their deflection can be achieved via a small, inexpensive, sta-
tionary permanent magnet. Previously, we have demonstrated 
their use for streptavidin-biotin binding assays,34,35 immuno-
globulin G (IgG) assays,35,36 DNA hybridisation,36,37 and pol-
ymer deposition.38 Other groups have also developed similar 
systems utilizing “zig-zag”-based magnetic particle deflection 
for assays,39-42 the capture of oligonucleotides43 and cells,44 
DNA extraction45,46 and particle coating.47,48 
 Here, we demonstrate the first application of our 
multilaminar flow platform for the rapid detection of CRP via 
a sandwich immunoassay (Figure 1c). Primary antibody func-
tionalised magnetic particles are introduced into a chamber in 
the x-direction and deflected in the y-direction via a magnet, 
crossing consecutive streams of CRP (standard or sample), 
washing buffer, fluorescently labelled secondary antibody, and 
into a final washing buffer. We first investigate the optimisa-
tion of various parameters, before performing assays on real 
human serum samples. Furthermore, we compare those results 
to data obtained by traditional ELISA techniques for valida-
tion of our system. 
 
EXPERIMENTAL 
Chip fabrication and setup 
The microfluidic chip design consisted of five inlet channels 
and five outlet channels connected to an 8 x 3 mm2 deflection 
chamber, which was supported by ten square posts (Figure 
2a). The devices were fabricated in glass (Telic, USA) to a 
depth of 20 µm using standard photolithography and wet etch-
ing procedures.49 Access holes were drilled into the glass 
plate, which was thermally bonded to a glass top plate (Figure 
2b). The chip was inserted into an aluminium chip holder that 
was fabricated in-house (Figure 2c), and which allowed inter-
facing of the access holes to fused silica capillaries (150 µm 
i.d., 363 µm o.d., CM Scientific, UK). The inlet capillaries 
were attached at the other end to syringes, which were placed 
on a syringe pump (PHD 22/2000, Harvard Apparatus, UK). 
The outlet capillaries had Tygon tubing (0.254 mm i.d., Cole-
Parmer, UK) connected to them, and this was fed into a waste 
collection vial. Solutions were pumped through the microflu-
idic chip at a flow rate of 20-100 µL h-1 per syringe, giving a 
total flow rate of 100-500 µL h-1 (458-2291 µm s-1) in the 
chamber. 
An inverted fluorescence microscope (TE-2000, Nikon, 
UK) with a CCD camera (Retiga-EXL, Media Cybernetics, 
UK) was used to capture images and videos, which were ana-
lysed using ImageJ software (http://rsb.info.nih.gov/ij/). Ex-
periments were typically performed at room temperature (20 
°C), but during some tests the temperature was varied using a 
temperature controlled sample stage (PE100-NIF, Linkam 
Scientific Instruments Ltd., UK). In this case, the chip holder 
was not used, and instead the capillaries were glued directly 
into the access holes of the chip using Araldite Epoxy glue 
(RS Components, UK) so that the chip could be in contact 
with the heated stage. 
A 4 x 4 x 5 mm3 rectangular neodymium-iron-boron 
(NdFeB) magnet (Magnet Sales, UK) was placed on top of the 
microfluidic chip, next to the deflection chamber. A set of 
rulers designed into the chip were used for positioning of the 
magnet. The magnetic flux density (B) at the surface of the 
 
Figure 1. (a) Principle of the two-step C-reactive protein sandwich im-
munoassay. (b) Schematic of a conventional off-chip magnetic particle-
based assay, including multiple washing steps. (c) Operation of the 
multilaminar flow platform for a CRP sandwich assay, in which func-
tionalized magnetic particles are pulled through alternating streams of 
reagents and washing buffers via an external magnet. 
Figure 2. (a) Schematic of the microfluidic device, showing the five 
inlets and five outlets, the reaction chamber, and the ruler structures used 
for positioning of the magnet. (b) Photograph of the device fabricated in 
glass, with a 4 x 4 x 5 mm3 NdFeB magnet positioned on top of the chip. 
(c) Photograph of the microfluidic device situated in a custom-built chip 
holder, with capillaries interfaced via nuts and ferrules to the access holes 
of the chip. 
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magnet was calculated to be 561 mT. A simulation of B across 
the deflection chamber of the chip (Figure 3) was prepared 
using FEMM 4.2 software (http://femm.foster-miller.net), and 
this was used to estimate a representative value of B at the 
centre of the chamber of 136 mT, with a gradient (∇B) across 
the chamber of 44 mT mm-1, and an estimated (B•∇)B value 
of 6 T2 m-1.  
Preparation of solutions and particle suspensions 
All solutions were prepared in high purity water (18.2 MΩ 
cm at 25 °C, 0.05 µm filtered) unless otherwise stated. Phos-
phate buffered saline solution (PBS, pH 7.45) was prepared 
with 0.01 % w/v bovine serum albumin (BSA) added to re-
duce non-specific binding of reagents and particles sticking. 
C-reactive protein (CRP, R&D Systems, UK) solutions were 
prepared in PBS buffer to concentrations of 1–10 µg mL-1. 
Biotinylated primary CRP antibody (1° Ab, R&D Systems) 
was prepared in PBS buffer to concentrations of 1–15 µg mL-1. 
Fluorescently labelled secondary CRP antibody (2° Ab-FITC, 
Abcam, UK) was prepared in PBS buffer to concentrations of 
10–200 µg mL-1. 
Human serum samples were collected from three volunteers 
and stored at -20 °C until ready for use. The samples were 
fully anonymized and no clinical details were recorded, and 
had been obtained as part of an ethically approved earlier 
study in circulating biomarkers in colorectal cancer patients. 
Streptavidin functionalised magnetic particles (Dynabeads 
M-270 Streptavidin, 2.8 µm diameter) were purchased from 
Invitrogen. 10 µL of stock particle suspension in a polypro-
pylene tube (VWR, UK) was mixed with 200 µL of 1° Ab 
solution at a concentration between 1–15 µg mL-1, then incu-
bated for 15 min to bind the biotinylated antibodies particle 
surface. The “activated” particles were then washed three 
times with PBS buffer, then resuspended in PBS buffer solu-
tion (1000 µL) to yield a final particle concentration of 6.7 x 
106 particles mL-1. 
Off-chip C-reactive protein assays 
The CRP sandwich immunoassay was optimised off-chip 
prior to performing the assay in the microfluidic device. 200 
µL of the activated (1° Ab) magnetic particle suspension was 
added to a polypropylene tube, the particles collected at the 
side of the tube via a magnet, and the supernatant was re-
moved. 200 µL of CRP (1–10 µg mL-1) was added and incu-
bated for 15 min with agitation. Following this, the particles 
were again pulled to the side of the tube via a magnet, and the 
particles washed three times with PBS. 200 µL solution of 2° 
Ab-FITC (10–200 µg mL-1) was added and allowed to incu-
bate for 15 min with agitation, then the particles washed three 
times with PBS, finally being resuspended in 1000 µL PBS. 
Samples were taken at various stages of the process and pipet-
ted onto a microscope slide for fluorescence analysis. 
On-chip C-reactive protein assay 
Prior to on-chip experiments, the microfluidic chip was 
washed consecutively with ethanol, water, and PBS buffer. 
Following this, activated (1° Ab) magnetic particles (6.7 x 106 
particles mL-1) was pumped into inlet 1, CRP solution into 
inlet 2, secondary antibody solution (2° Ab-FITC) into inlet 4, 
and PBS buffer solution into inlets 3 and 5, via the syringe 
pump. The effects of 2° Ab-FITC (1-100 µg mL-1) and CRP 
(1-10 µg mL-1) concentration were studied, while the effect of 
temperature was also examined at 20 °C and 40 °C. Human 
serum samples were tested by introducing the serum into inlet 
2 of the device, replacing the CRP standard solutions. 
ELISA analysis of human serum samples 
In order to compare on-chip results of the human serum 
samples, they were also tested using a hs-CRP ELISA test kit 
from MP Biomedicals (Fisher Scientific, UK) as per the manu-
facturer’s instructions. The presence of CRP yielded a yellow 
colour, the intensity of which was directly proportional to the 
concentration of CRP. 
 
RESULTS 
Off-chip C-reactive protein assays 
Off-chip assays were performed in order to ensure that the 
proposed magnetic particle-based method was suitable for the 
detection of CRP. Particular attention was paid to the parame-
ters of the particle activation step, in which the magnetic parti-
cles were functionalised with biotinylated primary CRP anti-
body (1° Ab), and which would take place off-chip prior to the 
introduction of the particles into the microfluidic device. 
Firstly, the concentration of 1° Ab during the preparation of 
the magnetic particles was varied from 1 to 15 µg mL-1 and 
incubated for 15 min, before completion of the sandwich assay 
([CRP] = 10 µg mL-1, [2° Ab-FITC] = 100 µg mL-1). The re-
sulting fluorescence intensities of the magnetic particles were 
measured and demonstrated that the fluorescence signal start-
ed to plateau at ~10 µg mL-1 of 1° Ab (Figure S-2a in the SI). 
Therefore, 10 µg mL-1 was employed for the activation step 
for all subsequent experiments. The incubation time of the 1° 
Ab activation step was also varied from 1 to 30 min to deter-
mine its effect ([1° Ab] = 10 µg mL-1, [CRP] = 10 µg mL-1, 
[2° Ab-FITC] = 100 µg mL-1). The resulting fluorescence in-
tensities of the particles actually showed little difference (Fig-
ure S-2b in the SI), indicating fast kinetics that would be ex-
pected of the streptavidin-biotin interaction. However, to en-
sure saturation of the antibody, the incubation time was kept at 
15 min for all subsequent experiments. 
Optimisation of the CCD camera exposure time was under-
taken by measuring the fluorescence intensity of reacted parti-
cles with exposure times ranging from 0.1 to 2 s. By compar-
ing the ratios of the particle intensities against the background 
 
Figure 3. Simulation of the magnetic flux density across the microfluidic 
chamber, modelled using FEMM software. 
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intensities, it was found that an exposure time of 0.7 s yielded 
the best results in terms of signal-to-noise ratio (Figure S-3a,b 
in the SI). Exposure times >1 s yielded lower intensities, pre-
sumably due to photobleaching (Figure S-3c in the SI), giving 
further evidence for employing an exposure time of 0.7 s, 
which was used for the remainder of the experiments. 
Negative control tests were also performed in which one of 
the reagents (1° Ab, CRP, 2° Ab-FITC) in each test was re-
placed with PBS buffer. The results showed no increase in 
fluorescence intensity, indicating that the reaction did not oc-
cur without the presence of all of the reagents. 
These off-chip tests confirmed the applicability of the mag-
netic particle-based CRP assay, and allowed the optimisation 
of the particle activation step. Furthermore, they highlighted 
the laborious nature of the off-chip assays, such as the multi-
ple manual steps required, the relatively large volumes of rea-
gents employed (200 µL), and the long assay times (~50 min). 
Effect of flow rate on diffusion and particle trajectories 
The laminar flow regime inside the chamber was studied by 
introducing alternating streams of red and yellow inks into the 
device at applied flow rates (i.e. the flow rate from each indi-
vidual syringe) from 1-100 µL h-1, corresponding to flow rates 
in the chamber of 5-500 µL h-1 (22.9-2291 µm s-1). Stable flow 
was observed across all of the flow rates (Figure S-4a in the 
SI), and no diffusion was observed between streams 2 (repre-
senting CRP) and 4 (representing 2° Ab-FITC) at flow rates in 
the chamber down to 50 µL h-1 in the chamber. However, at 
the lowest applied flow rate tested of 5 µL h-1 (in the cham-
ber), the diffusion of the streams became problematic, with the 
contents of streams 2 and 4 actually crossing stream 3 and 
starting to mix with each other (Figure S-4b in the SI). This 
was confirmed by plotting the greyscale values across the 
width of the chamber near to the outlet  using ImageJ software 
(Figure S-4c in the SI). Thus, provided the chamberflow rates 
were 50 µL h-1 or higher, diffusion between reagent streams 
would not be problematic. 
The magnetic particle trajectories were also examined at dif-
ferent flow rates in the presence of the stationary NdFeB mag-
net next to the chamber. Particle suspension was pumped into 
inlet 1 of the device with PBS buffer introduced into the re-
maining outlets (2-5), and the flow rate of the solutions in the 
chamber was varied from 100 to 500 µL h-1 (458 to 2291 µm 
s-1) (Figure S-5 in the SI). The results showed that the particles 
at a flow rate of 500 µL h-1 and 250 µL h-1 were unable to 
cross the entire width of the chamber, while at 100 µL h-1 they 
migrated across the entire width but then aggregated against 
the top wall (in the y-direction) of the chamber. The optimum 
flow rate was thus between these, and was determined to be 
200 µL h-1 (916 µm s-1). 
Flow and diffusion simulations 
Having established that 200 µL h-1 was the optimum flow 
rate in the chamber (i.e. 40 µL h-1 on the syringe pump) for 
magnetic particle deflection, the diffusion of the reagent spe-
cies across the chamber at this flow rate was simulated. The 
simulations were prepared in COMSOL Multiphysics 4.0a, 
and showed the diffusion of CRP and 2° Ab-FITC from 
streams 2 and 4, respectively (Figure 4). Further details of the 
model parameters are given in the SI. It should be noted that 
Figure 4 was constructed from superimposed simulations for 
the two reagent streams, while the originals can be found in 
the SI (Figures S-6a,b). The concentration profiles of the 2° 
Ab-FITC and CRP streams across the width of the chamber, 
600 µm from the outlets, were plotted from the individual 
simulations (Figure S-6c in the SI). These plots confirmed that 
the diffusion of the two species was not sufficient to allow 
mixing across the central buffer stream. Simulations of the 
velocity magnitude (Figure S-7a) and the pressure (Figure S-
7b) across the microfluidic chamber were also plotted, and 
these can be seen in the SI. 
On-chip C-reactive protein assay 
Figure 4. Superimposed simulations showing the diffusion of CRP and 
2° Ab-FITC they pass through the microfluidic chamber. The original, 
individual simulations can be found in the ESI (Fig. S6), together with 
their respective legends. 
 
Figure 5. (a) Chip schematic demonstrating the reagents and washing buffers being pumped  into the device, and the locations  at which photographs of 
particles were taken (b) before and while entering the 2° Ab-FITC stream, and (c) after the particles had been deflected through the laminar flow streams. 
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Having established the optimum flow rate, the solutions in 
the chamber were replaced with 1° Ab activated magnetic 
particles in inlet 1, CRP in inlet 2, 2° Ab-FITC in inlet 4, and 
PBS buffer in inlets 3 and 5. The magnetic particles were de-
flected across the width of the chamber towards the stationary 
magnet as they followed the direction of flow, crossing each 
of the reagent and washing laminar flow streams in turn (Fig-
ure 5a). This allowed consecutive binding of CRP, washing, 
labeling, and a final washing step. Fluorescence images of the 
particles were taken before (Figure 5b) and after (Figure 5c) 
passing through the 2° Ab-FITC stream, and demonstrate the 
increase in fluorescence intensity that indicated successful 
CRP binding and labelling. 
A series of negative tests were performed in which one of 
the reagents (1° Ab, CRP, 2° Ab-FITC) was removed from the 
procedure each time and replaced with PBS buffer solution 
instead. In each case the particles did not exhibit higher fluo-
rescence intensities than their auto-fluorescence values, show-
ing that the assay would not work without having all of the 
components present. This also demonstrated that the final PBS 
washing stream was sufficient to wash any unbound 2° Ab-
FITC as no fluorescence increase was observed when CRP 
was not present. 
Importantly, the assay procedure, i.e. the crossing of the 
particles across the width of the reaction chamber, took only 
around 60 seconds, a vast reduction in processing time that 
would normally be required using conventional techniques 
such as off-chip magnetic particle assays and ELISA. In addi-
tion, manual operations were virtually eliminated since once 
the solutions and particles were being pumped through the 
chip the procedure was essentially autonomous. 
In a separate test, the particles were collected from the chip 
and their fluorescence intensities were compared to particles 
that had been reacted using the conventional off-chip tech-
nique (Figure 6a). The fluorescence intensities were found to 
be very similar, indicating that the efficiency of the on-chip 
reaction was similar to the conventional method, even with the 
much shorter incubation times (60 s) in the former case. 
Effect of secondary antibody concentration 
The effect of 2° Ab-FITC concentration in the on-chip assay 
was investigated by repeating the experiment with varying 
concentrations (1–100 µg mL-1) of 2° Ab-FITC, while the 
CRP concentration was maintained at 1 µg mL-1. The results 
are shown in Figure 6b, and demonstrated little change in the 
fluorescence signal of the particles between across the concen-
tration range. The signal showed a very slight increase at 100 
µg mL-1 of 2° Ab-FITC, which may have ensured saturation of 
the CRP binding sites more effectively than lower concentra-
tions. Although the concentration of 2° Ab-FITC was appar-
ently not a vital factor for the assay in the range tested, it was 
decided that 100 µg mL-1 would be used in further experi-
ments to ensure saturation of any particle-bound CRP. 
Effect of temperature on the on-chip assay 
Immunoassays are often performed at 37 °C, however the 
optimisation of the magnetic particle-based assays had taken 
place at room temperature (20 °C). In order to determine 
whether increasing the temperature had an effect on the on-
chip CRP immunoassay ([CRP] = 1 µg mL-1, [2° Ab-FITC] = 
100 µg mL-1), the experiment was repeated at temperatures of 
20 °C and 40 °C using a temperature controlled sample stage. 
The temperature stage was calibrated by varying the pro-
grammed temperature while measuring the temperature of the 
stage and chip using a thermocouple (Figure S-8 in the SI). 
The resulting fluorescence intensities were normalised with 
respect to the unreacted particles, and are shown in Figure 6c. 
The results showed that increasing the temperature had very 
little effect, with only a very minor increase in intensity ob-
served at 40 °C. Therefore, the remainder of the on-chip ex-
periments were performed at room temperature (20 °C). 
Figure 6. (a) Comparison of magnetic particle fluorescence intensities between those reacted off-chip, and those reacted on-chip then collected for off-chip 
analysis. (b) Effect of secondary antibody concentration (2° Ab-FITC) on fluorescence intensity in multilaminar flow assays. (c) Effect of temperature on 
the multilaminar flow sandwich assays. 
 
Figure 7. Calibration curve of fluorescence peak area versus CRP concen-
tration generated via the on-chip multilaminar flow assay (n = 5 particles). 
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C-reactive protein calibration 
In order to determine the validity of the platform for quanti-
tative assays, and for the determination of CRP concentrations 
in real human serum samples, experiments were repeated with 
CRP concentrations of 1, 5 and 10 µg mL-1. The concentration 
of 2° Ab-FITC was 100 µg mL-1. The plotted results are 
shown in Figure 7, and the graph clearly demonstrates a linear 
increase of fluorescence signal with increasing CRP concen-
tration. The “fluorescence peak area” rather than fluorescence 
intensity was measured since the captured images showed 
“streaks” of particles, and the peak area better accounted for 
differences in particle velocities, since faster particle yield 
longer streaks. 
Based on the standard deviation of the intercept 
(α = 0.02591), and the gradient (S = 0.09871), the limit of 
detection (LOD) of the platform was determined to be 0.87 µg 
mL-1, given that LOD = (3.3α)/S.50 This shows that the lowest 
CRP concentration tested here (1 µg mL-1) was near to the 
LOD, but was well within the limits for conventional CRP 
testing. Furthermore, the technique should also be capable of 
performing hs-CRP tests, since the LOD is below the thresh-
old value for low risk of CVD (<1 µg mL-1). Having estab-
lished a calibration curve, the determination of CRP in real 
human serum samples was investigated. 
Human serum samples 
Serum samples were collected from three volunteers and 
pumped into inlet 2 of the microfluidic chip during the on-chip 
assay. Despite the viscosity of the serum being higher than 
water, the magnetic particles could be easily deflected through 
the serum stream. After then passing through the washing and 
2° Ab-FITC (100 µg mL-1) streams, the fluorescence peak 
areas of the moving particles were measured and their corre-
sponding CRP concentrations determined from the graph in 
Figure 7. These CRP values are shown in Table 1 alongside 
the CRP concentrations determined via conventional ELISA 
analysis of the same samples. The calibration curve and real 
sample values obtained from the ELISA analysis are shown in 
Figure S-9 and Table S-1, respectively, in the SI. As before, 
the assay took less than 60 s, the time required for particles to 
cross the width of the chamber. 
 
Table 1. Fluorescence peak areas of magnetic particles following 
multilaminar flow assays, their corresponding CRP concentrations (n = 
5 particles), and CRP concentrations determined by ELISA (n = 2). 
 
Sample 
no. 
On-chip 
fluorescence 
peak area (a.u.) 
Concentration of CRP  
(µg mL-1) 
On-chip ELISA 
1 0.577 ± 0.043 1.47 ± 0.11 1.52 ± 0.13 
2 0.678 ± 0.132 2.49 ± 0.48 2.63 ± 0.12 
3 1.044 ± 0.167 6.20 ± 0.99 5.29 ± 0.02 
 
The CRP concentrations determined for samples 1 and 2 
matched closely between the on-chip and ELISA techniques, 
but that of sample 3 was not quite so close. Therefore, a two-
tailed t-test was performed to compare the results of the two 
testing methods for each sample. In all three cases, it was de-
termined that the t-values were less than their corresponding 
critical values at P = 0.05, indicating no significant difference 
between the CRP values obtained by multilaminar flow tech-
nique and those from the standard ELISA method. These re-
sults demonstrate the applicability of the multilaminar flow 
platform to the measurement of real human serum samples. 
This bodes well for future development of the system for as-
saying a number of biomarkers, while improvements to the 
setup should allow increases in performance in terms of the 
limits of detection, precision of the measurements, versatility, 
and user-friendliness. 
 
DISCUSSION AND OUTLOOK 
The magnetic multilaminar flow platform has been demon-
strated for the detection of clinically relevant biomarker from 
real human serum samples. The great benefit of the platform is 
the speed with which the assay takes place, less than 60 s, due 
to the elimination of the multiple manual manipulation steps 
and long diffusion-based reaction times required in off-chip 
magnetic particle assays and in ELISA tests. The multilaminar 
flow technique combines reaction and washing steps into a 
single, automated process, with the assay time determined by 
how long it takes for the particles to cross the width of the 
chamber. This rapid assay time is enabled by directly trans-
porting fresh reagents to the particle surfaces as they move 
through the reagent streams, rather than relying on diffusion of 
reagents within a relatively large volume well or vial. 
Furthermore, while small sample volumes can be used in 
ELISA (5 µL), reagent and washing volumes can still be rela-
tively large (≥300 µL), and in off-chip magnetic particles each 
step requires large volumes (≥200 µL). In contrast, running the 
multilaminar flow system for around 5 min to ensure enough 
particles have passed through the chip for analysis will only 
use sample and reagent volumes of 0.7 µL at 40 µL h-1. Sever-
al more µL per syringe will also be required due to dead vol-
umes (~3.7 µL) and while waiting for the system to stabilize, 
but a typical volume should still be <10 µL and this remains a 
large decrease compared to the conventional methods. A 
summary of typical timeframes and solution volumes for each 
of the CRP measurement methods (ELISA, off-chip magnetic 
particle assays, and on-chip multilaminar flow assays) is given 
in Table 2, and demonstrates the benefits of the multilaminar 
flow technique compared to the others. Not only this, but the 
platform allows faster analyses than other microfluidic meth-
ods, and while other such techniques have lower detection 
limits this is not actually necessary for CRP assays. While we 
have only investigated lower concentration ranges here, corre-
sponding to CVD monitoring, the technique can distinguish 
whether levels fall below or above 10 µg mL-1, thereby indi-
cating whether inflammation or infection is present. It should 
also be feasible to determine whether the source of infection is 
bacterial (> 40 µg mL-1) but it was not our intention to study 
this. One issue that may arise from investigating such high 
concentrations could be saturation of the signal. However, 
given that we are operating in the region of ~35 a.u. fluores-
cence intensities for our 10 µg mL-1 standards, and that the 
maximum is 255 a.u., it is expected that even at 40 µg mL-1 
saturation would not occur. A different issue could be the satu-
ration of antibodies of the particle surface, and this would 
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require re-optimisation of some parameters or dilution of the 
sample. 
While the multiflow system has many advantages, there are 
also aspects that require further consideration and optimisation 
in future. The trajectories of the particles could be made more 
reproducible by incorporating a flow focusing design for parti-
cle introduction, ensuring that all particles enter the chamber 
at the same position. The magnet could be placed next to the 
chamber, rather than on top of the chip, to ensure particles 
travel in the same horizontal plane instead of at different 
depths. These would help to eliminate discrepancies in particle 
intensity due to the “streaking” effect described earlier. Fur-
ther improvements could include automation of the particle 
analysis, which is currently performed manually in ImageJ. 
However, while we currently employ a fluorescence micro-
scope for image collection and analysis, we foresee the use of 
miniaturised fluorescence detection systems51,52 since we 
would not need to image a large area, instead requiring only 
that the magnetic particles pass through a small detection zone 
(such as that offered by laser-induced fluorescence detection). 
Furthermore, initial setup times for the platform, currently 
quite long at up to 45 min (including all steps such as binding 
primary antibodies to magnetic particles, preparation of chip 
and interfacing, washing of chip), could be significantly im-
proved. This could be achieved by introducing an extra 
multilaminar flow reaction step to bind the primary antibodies 
to the magnetic particles on-chip rather than off-chip, while 
the set up with the syringes and syringe pump could also be 
improved. 
However, these potential improvements represent a longer 
term vision for the system, while even in its current state it has 
proven capable of performing clinically relevant assays. We 
envisage the application of the system for the detection of a 
variety of biomarkers the patient’s bedside, while requiring 
only a small volume of sample. 
 
Table 2. Comparison of experimental parameters between conven-
tional ELISA tests, off-chip magnetic particle assays, and the on-chip 
multilaminar flow assay for CRP determination. 
 
 ELISA Off-chip On-chip 
CRP binding step 45 min 15 min 6 – 10 s 
Labelling step 20 min 15 min 6 – 10 s 
Washing steps 15 min 20 min 12 – 20 s 
Total time 80 min 50 min < 1 min 
Volume of sample 5 µL 200 µL < 10 µL 
Volume of reagents 300 µL 200 µL < 10 µL 
Volume of wash soln. 1.5 mL 1.8 mL < 30 µL 
Volume of waste 1.9 mL 2.2 mL < 50 µL 
 
CONCLUSIONS 
We have demonstrated the application of a multilaminar 
flow platform, in which functionalised magnetic particles are 
pulled through alternating streams of reagents and washing 
buffers, for the quantitative detection of the inflammatory 
biomarker C-reactive protein from human serum samples. The 
two-step sandwich immunoassay required only 60 seconds, the 
time taken for the particles to cross the chamber through each 
of the streams. This is a vast improvement on conventional 
magnetic particle-based assay procedures, and removes the 
laborious manual operations usually required in such tech-
niques. The detection of a clinically relevant biomarker opens 
the door for its application to the detection of a wider range of 
important biomolecules in rapid timeframes and with minimal 
sample and reagent usage.  
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